SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Seribantumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SHERLOC
- Sponsors Merrimack Pharmaceuticals
- 25 Jun 2018 According to a Merrimack Pharmaceuticals media release, Top-line results from the SHERLOC study are expected in 2H 2018.
- 07 May 2018 Eudra reports planned patient number, 135. I have not changed since it was updated from MR.
- 07 May 2018 Last checked against Clinicaltrials.gov record.